Jane Street Group LLC Increases Position in Immunic, Inc. (NASDAQ:IMUX)

Jane Street Group LLC lifted its position in shares of Immunic, Inc. (NASDAQ:IMUX) by 121.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,299 shares of the company’s stock after purchasing an additional 38,553 shares during the period. Jane Street Group LLC’s holdings in Immunic were worth $116,000 at the end of the most recent reporting period.

Separately, State Street Corp raised its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Immunic news, Director Richard Alan Rudick acquired 87,300 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.00% of the company’s stock.

Immunic Price Performance

Shares of IMUX stock opened at $1.00 on Wednesday. The company’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.32. The firm has a market capitalization of $90.08 million, a P/E ratio of -0.81 and a beta of 1.88. Immunic, Inc. has a 12 month low of $0.97 and a 12 month high of $2.11.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.